Steven J Steiner
Overview
Explore the profile of Steven J Steiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adler J, Galanko J, Ammoury R, Benkov K, Bousvaros A, Boyle B, et al.
Am J Gastroenterol
. 2024 Oct;
PMID: 39423015
Objectives: HLA DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNF) and treatment failure among adults with Crohn's disease (CD). However, findings...
2.
Moses J, Adler J, Saeed S, Firestine A, Galanko J, Ammoury R, et al.
Inflamm Bowel Dis
. 2024 Oct;
PMID: 39418336
Background: Higher drug levels and combination therapy with low-dose oral methotrexate (LD-MTX) may reduce anti-tumor necrosis factor (TNF) treatment failure in pediatric Crohn's disease. We sought to (1) evaluate whether...
3.
Price A, Simmons H, Gehring E, Davis L, Fischer G, Klipsch A, et al.
Contemp Clin Trials
. 2024 Sep;
146:107701.
PMID: 39326578
Background: Significant barriers to advancing pediatric drug development continue despite federal incentives to expedite pediatric drug development. There is an urgent need to improve how clinical trials are designed, implemented,...
4.
McLaughlin J, Linville T, Jester T, Marciano T, Lazare F, Dotson J, et al.
Clin Gastroenterol Hepatol
. 2024 Aug;
PMID: 39181423
Background & Aims: Delayed diagnosis of inflammatory bowel disease (IBD) leads to prolonged symptoms and worse long-term outcomes. We sought to evaluate whether race, ethnicity, disease type, and social factors...
5.
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease
Ebach D, Jester T, Galanko J, Firestine A, Ammoury R, Cabrera J, et al.
Am J Gastroenterol
. 2024 Mar;
119(6):1110-1116.
PMID: 38445644
Introduction: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares...
6.
Singh N, Steiner S, Fauth R, Moosmann D, Arnold J, Elkadri A, et al.
Crohns Colitis 360
. 2023 Sep;
5(3):otad042.
PMID: 37691728
Background: Camp Oasis is an annual week-long camp serving children with inflammatory bowel disease (IBD) and hosted by the Crohn's and Colitis Foundation. Youth with IBD are at increased risk...
7.
Kappelman M, Wohl D, Herfarth H, Firestine A, Adler J, Ammoury R, et al.
Gastroenterology
. 2023 Apr;
165(1):149-161.e7.
PMID: 37004887
Background & Aims: Tumor necrosis factor inhibitors, including infliximab and adalimumab, are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of response are common. As combination therapy...
8.
Zhang N, Liu C, Steiner S, Colletti R, Baldassano R, Chen S, et al.
J Comp Eff Res
. 2023 Feb;
12(4):e220136.
PMID: 36799351
To evaluate the performance of the multiple imputation (MI) method for estimating clinical effectiveness in pediatric Crohn's disease in the ImproveCareNow registry; to address the analytical challenge of missing data....
9.
Hunter T, Komocsar W, Liu C, Colletti R, Steiner S, Dotson J, et al.
Crohns Colitis 360
. 2023 Feb;
4(2):otac009.
PMID: 36777044
Background: To assess disease activity, steroid-free remission, and other clinical outcome assessments among pediatric patients with ulcerative colitis (UC) and Crohn's disease (CD) in the ImproveCareNow (ICN) registry. Methods: Patients...
10.
Hunter T, Komocsar W, Colletti R, Liu C, Benkov K, Dotson J, et al.
Curr Med Res Opin
. 2022 Oct;
39(1):63-69.
PMID: 36263735
Objectives: To assess treatment patterns and initial and maintenance dosing of biologics over 3 years in pediatric patients with ulcerative colitis (UC) or Crohn's disease (CD), utilizing data from the...